Good Steward Wealth Advisors LLC Sells 1,797 Shares of Johnson & Johnson $JNJ

Key Points

• Good Steward Wealth Advisors LLC has reduced its holdings in Johnson & Johnson by 39.9%, selling 1,797 shares during the 2nd quarter, leaving them with 2,703 shares valued at approximately $413,000.
• Several institutional investors have increased their stakes in Johnson & Johnson, notably Scissortail Wealth Management LLC, which expanded their holdings by 5,251.2% within the same period.
• Analysts have a consensus rating of "Moderate Buy" for Johnson & Johnson, with price targets ranging from $167.00 to $200.00 following recent positive earnings results and stock performance.

Good Steward Wealth Advisors LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 39.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,703 shares of the company's stock after selling 1,797 shares during the quarter. Good Steward Wealth Advisors LLC's holdings in Johnson & Johnson were worth $413,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JNJ. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC lifted its holdings in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares in the last quarter. Shell Asset Management Co. lifted its stake in shares of Johnson & Johnson by 6.2% in the 4th quarter. Shell Asset Management Co. now owns 10,725 shares of the company's stock valued at $1,551,000 after purchasing an additional 630 shares during the period. Scissortail Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 5,251.2% in the 4th quarter. Scissortail Wealth Management LLC now owns 21,726 shares of the company's stock valued at $3,142,000 after purchasing an additional 21,320 shares during the period. Finally, Safe Harbor Fiduciary LLC lifted its stake in shares of Johnson & Johnson by 1.7% in the 4th quarter. Safe Harbor Fiduciary LLC now owns 6,152 shares of the company's stock valued at $890,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Wall Street Zen raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday. UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Price Performance

JNJ stock opened at $178.10 on Friday. The stock has a 50-day moving average price of $170.81 and a two-hundred day moving average price of $161.29. The stock has a market cap of $428.93 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.